Michael Gelband’s Array Biopharma Inc ARRY Stock Holding History

Michael Gelband’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-68,002	Closed	-$969K	–	806
2018 Q4	$969K	Buy	+68,002	New	+$1.03M	0.07%	92

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Michael Gelband's ARRY Position: Q1 2019 in Review

Michael Gelband sold out of Array Biopharma Inc (ARRY) in Q1 2019, closing a stake of 68,002 shares — an estimated $969K sold.

Michael Gelband first reported a position in ARRY in Q4 2018 and held it in 1 quarter. The position peaked at $969K in Q4 2018. 268 funds tracked by Wall St. Rank hold ARRY as of Q1 2019.

Michael Gelband reported no remaining Array Biopharma Inc position as of Q1 2019 after selling out during the quarter.
Michael Gelband sold 68,002 Array Biopharma Inc shares in Q1 2019, an estimated $969K.
Michael Gelband first reported a position in Array Biopharma Inc in Q4 2018 and held it in 1 quarter.
Michael Gelband's Array Biopharma Inc position peaked at $969K in Q4 2018.
268 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2019.

Based on ExodusPoint Capital Management's 13F filing for Q1 2019, filed 15 May 2019.